“Before the end of the year, we look forward to reporting several significant milestones: contracting with a clinical research organization for our Phase 2 study of oral Endoxifen to treat MBD, completing additional.."CEO of $ATOSatossagenetics.com/atossa-ge…$IBB$ACST$AMRN#stocks